| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| lenalidomide | cadherin-5 | small molecule | NA | drugbank | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | antagonist |
| lenalidomide | cadherin-5 | small molecule | NA | drugbank | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | antagonist |
| lenalidomide | protein cereblon | small molecule | NA | drugbank , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.79 | approved | inhibitor |
| lenalidomide | protein cereblon | small molecule | NA | drugbank , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.79 | approved | inhibitor |
| lenalidomide | prostaglandin g/h synthase 2 | small molecule | NA | drugbank | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | negative modulator |
| lenalidomide | prostaglandin g/h synthase 2 | small molecule | NA | drugbank | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
NA | approved | negative modulator |
| lenalidomide | tumor necrosis factor | NA | Successful target | TTD , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.13 | approved | unknown |
| lenalidomide | tumor necrosis factor | NA | Successful target | TTD , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
0.13 | approved | unknown |
| lenalidomide | tumor necrosis factor ligand superfamily member 11 | small molecule | NA | drugbank , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Coronavirus Infections[MeSHID:D018352] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.41 | approved | inhibitor |
| lenalidomide | tumor necrosis factor ligand superfamily member 11 | small molecule | NA | drugbank , DGIDB | Congenital chromosomal disease[MeSHID:D025063] Disease[MeSHID:D004194] Maintenance[MeSHID:D008283] Mucosa-Associated Lymphoid Tissue Lymphoma[MeSHID:D018442] Malignant lymphoma lymphocytic intermediate differentiation diffuse[MeSHID:D020522] MYELODYSPLASTIC SYNDROME[MeSHID:D009190] Chromosome Aberrations[MeSHID:D002869] Deletion Mutation[MeSHID:D017384] Anemia[MeSHID:D000740] Multiple Myeloma[MeSHID:D009101] Lymphoma Follicular[MeSHID:D008224] Relapse[MeSHID:D012008] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] |
3.41 | approved | inhibitor |
| click here to return to the previous page | ||||||||